Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-08-02
Based on 513 first isolates · MED-A · Cystitis (lower UTI) · 2025-08-03 → 2026-08-02
Internal medicine A
Per-organism detail: MED-A urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 84 % (80 %–87 %)
No tissue or blood levels: cystitis only.
Not covered: Klebsiella pneumoniae (6 %), Proteus mirabilis (5 %), Pseudomonas aeruginosa (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
84 %
87 %
n = 52
meropenem MEM
trend · Escherichia coli reserve
83 %
77 %
n = 52
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
77 %
n = 52
ciprofloxacin CIP
trend · Escherichia coli
77 %
71 %
n = 52
ceftriaxone CRO
trend · Escherichia coli
76 %
69 %
n = 52
mecillinam MEC
trend · Escherichia coli lower UTI only
76 %
69 %
n = 52
72 %
65 %
n = 52
trimethoprim TMP
trend · Escherichia coli lower UTI only
67 %
67 %
n = 52
47 %
40 %
n = 52
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
17 %
n = 52
4 %
2 %
n = 52
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
4 %
n = 52

Most likely organisms for this profile

Escherichia coli
56 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
5 %
Pseudomonas aeruginosa
4 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.